but also mentions several of Mirati’s other oncology candidates. Top of the list is PRMT5/MTA inhibitor MRTX1719, which BMS said could be a first-in-class therapy for cancers with MTAP deletions ...

PRMT5 inhibitor MRTX1719 for MTAP-deleted cancers, and selective SOS1 inhibitor MRTX0902. Last year, the Financial Times also reported that there was interest in a Mirati buyout, citing Merck as ...

Amgen and Ideaya Biosciences are winding down their cancer combination study, closing off one way the Big Biotech was looking to dial up the efficacy of its PRMT5 inhibitor AMG 193. The ...